Mallinckrodt Plc (MNK)

9.61
0.51 5.60
NYSE : Health Technology
Prev Close 9.10
Open 9.10
Day Low/High 8.83 / 9.73
52 Wk Low/High 8.45 / 36.65
Volume 3.72M
Avg Volume 2.52M
Exchange NYSE
Shares Outstanding 83.81M
Market Cap 773.60M
EPS -42.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Mallinckrodt Plc

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Mallinckrodt Plc

NEW YORK, May 22, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Mallinckrodt plc (NYSE: MNK) common stock from April 13, 2016 through May 21, 2019.

LOST MONEY IN MALLINCKRODT? Gibbs Law Group Investigates Potential Securities Claims On Behalf Of Investors

LOST MONEY IN MALLINCKRODT? Gibbs Law Group Investigates Potential Securities Claims On Behalf Of Investors

Mallinckrodt plc shares have declined by nearly 38% in 2019 due to issues with health regulators and accusations of kickbacks.

Mallinckrodt Announces Election Of Carlos V. Paya, M.D., Ph.D. To Its Board Of Directors

Mallinckrodt Announces Election Of Carlos V. Paya, M.D., Ph.D. To Its Board Of Directors

-- New member brings unique blend of industry expertise and clinical experience --

Mallinckrodt Is Circling the Drain - Do Not Go Down With It

Mallinckrodt Is Circling the Drain - Do Not Go Down With It

Let's examine a couple of charts.

Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel

Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel

The drugmaker files suit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services in order to protect Medicaid patient access to its Acthar gel.

Mallinckrodt Files Suit Against U.S. Department Of Health And Human Services (HHS) And Centers For Medicare And Medicaid Services (CMS) To Protect Medicaid Patient Access To Acthar® Gel

Mallinckrodt Files Suit Against U.S. Department Of Health And Human Services (HHS) And Centers For Medicare And Medicaid Services (CMS) To Protect Medicaid Patient Access To Acthar® Gel

-- Company challenges CMS' unexplained and unlawful reversal of its repeated 2012 written authorizations on calculation of Medicaid Rebates for Acthar Gel --

Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only

Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only

BMY is not 'out of the woods' yet, but aggressive traders could probe the long side here.

Rally With a Twist: Cramer's 'Mad Money' Recap (Wednesday 5/15/19)

Rally With a Twist: Cramer's 'Mad Money' Recap (Wednesday 5/15/19)

Jim Cramer says this market is influenced by tariffs and trade talks -- with the Federal Reserve and the economy playing second fiddle.

Applied Materials, HP, Lam Research: 'Mad Money' Lightning Round

Applied Materials, HP, Lam Research: 'Mad Money' Lightning Round

Jim Cramer takes a look at Applied Materials, HP, Lam Research, Schlumberger, PBF Energy, Targa Resources, Mallinckrodt and more.

MNK June 28th Options Begin Trading

MNK June 28th Options Begin Trading

Investors in Mallinckrodt plc saw new options begin trading today, for the June 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new June 28th contracts and identified one put and one call contract of particular interest.

Mallinckrodt Completes Enrollment Of Phase 3 Terlipressin CONFIRM Trial

Mallinckrodt Completes Enrollment Of Phase 3 Terlipressin CONFIRM Trial

-- Mallinckrodt's CONFIRM study is evaluating the efficacy and safety of terlipressin in hepatorenal syndrome type 1 --

Lifshitz & Miller LLP Announces Investigation Of Glencore Plc, Kingstone Companies, Inc., Mallinckrodt PLC, Metro Bank PLC, Momo Inc., Nabriva Therapeutics PLC, National General Holdings Corp, And Zillow Group, Inc.

Lifshitz & Miller LLP Announces Investigation Of Glencore Plc, Kingstone Companies, Inc., Mallinckrodt PLC, Metro Bank PLC, Momo Inc., Nabriva Therapeutics PLC, National General Holdings Corp, And Zillow Group, Inc.

NEW YORK, May 13, 2019 /PRNewswire/ -- Glencore plc (GLNCY) Lifshitz & Miller announces investigation into possible securities laws violations regarding allegations that GLNCY and other trading firms paid over $30 million in bribes to Petroleo Brasieiro S.

Mallinckrodt Plc Reports Strong Growth In First Quarter 2019 Results, Raises Guidance For 2019, And Continues To Make Significant Advancements In Pipeline And Data Generation

Mallinckrodt Plc Reports Strong Growth In First Quarter 2019 Results, Raises Guidance For 2019, And Continues To Make Significant Advancements In Pipeline And Data Generation

- Net sales up 4.7%, or 5.0% on a constant-currency basis, on $790.6 million, led by strong performance of hospital products and the Specialty Generics and Amitiza segment

Cancer Prevention Pharmaceuticals (CPP) And Mallinckrodt Announce Results From Pivotal Phase 3 Trial Of CPP-1X/Sulindac In Patients With Familial Adenomatous Polyposis

Cancer Prevention Pharmaceuticals (CPP) And Mallinckrodt Announce Results From Pivotal Phase 3 Trial Of CPP-1X/Sulindac In Patients With Familial Adenomatous Polyposis

-- Full data to be presented in detail by CPP at Digestive Disease Week (DDW) conference on May 19, 2019 at 5:19 pm Pacific Time --

Mallinckrodt Announces Encouraging Interim Analysis Results In Phase 4 Registry Of INOmax® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In Neonates

Mallinckrodt Announces Encouraging Interim Analysis Results In Phase 4 Registry Of INOmax® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In Neonates

-- Observational registry (at midway point) with retrospective data collection provides preliminary evaluation of premature versus term and near-term neonates with pulmonary hypertension receiving inhaled nitric oxide --

MALLINCKRODT (MNK) ALERT: Johnson Fistel, LLP Commences Investigation Of Mallinckrodt PLC; Encourages All Investors To Contact The Firm For Information

MALLINCKRODT (MNK) ALERT: Johnson Fistel, LLP Commences Investigation Of Mallinckrodt PLC; Encourages All Investors To Contact The Firm For Information

SAN DIEGO, May 2, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP has commenced an investigation into whether certain officers and directors of Mallinckrodt PLC (NYSE: MNK) violated federal laws.

MNK June 14th Options Begin Trading

MNK June 14th Options Begin Trading

Investors in Mallinckrodt plc saw new options become available today, for the June 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new June 14th contracts and identified one put and one call contract of particular interest.

Mallinckrodt To Present Open-Label Results From Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial In Patients With Rheumatoid Arthritis At Annual European Congress Of Rheumatology (EULAR 2019)

Mallinckrodt To Present Open-Label Results From Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial In Patients With Rheumatoid Arthritis At Annual European Congress Of Rheumatology (EULAR 2019)

-- Company also announces completion of controlled, double-blind, randomized phase (n=154; open-label phase, n=259) of multicenter study -

Interesting MNK Put And Call Options For June 21st

Interesting MNK Put And Call Options For June 21st

Investors in Mallinckrodt plc saw new options begin trading today, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new June 21st contracts and identified one put and one call contract of particular interest.

Mallinckrodt Completes Expansion Of Operations And Manufacturing Facility For StrataGraft® Regenerative Skin Tissue In Madison, Wis.

Mallinckrodt Completes Expansion Of Operations And Manufacturing Facility For StrataGraft® Regenerative Skin Tissue In Madison, Wis.

- Expanded state-of-the-art facility provides capacity for clinical and commercial development of StrataGraft, if approved -

Mallinckrodt Lupus Phase 4 Clinical Study For Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment In Difficult-to-Manage Population

Mallinckrodt Lupus Phase 4 Clinical Study For Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment In Difficult-to-Manage Population

-- Company continues focus on evidence expansion, potential utility of Acthar Gel in appropriate, underserved patients --

Mallinckrodt Reports Top-Line Results From Proof-of-Concept Study Of Nitric Oxide Gas In Ex-Vivo System Of Human Lung Transplants

Mallinckrodt Reports Top-Line Results From Proof-of-Concept Study Of Nitric Oxide Gas In Ex-Vivo System Of Human Lung Transplants

-- Study showed oxygenation improvement and increased out-of-body perfusion duration --

Data On Impact Of Revised Consensus Recommendations On Time To Treatment And Serum Creatinine (SCr) At Treatment Start For Patients With Hepatorenal Syndrome Type 1 (HRS-1) Presented At The 2019 International Liver Congress™ (EASL)

Data On Impact Of Revised Consensus Recommendations On Time To Treatment And Serum Creatinine (SCr) At Treatment Start For Patients With Hepatorenal Syndrome Type 1 (HRS-1) Presented At The 2019 International Liver Congress™ (EASL)

-- Retrospective analysis showed applying latest International Club of Ascites (ICA) diagnostic criteria would be estimated to result in earlier time to treatment at a lower SCr level and potentially improved outcomes --

Mallinckrodt Completes Full Enrollment Of Its Phase 3 Clinical Trial For StrataGraft® Regenerative Skin Tissue

Mallinckrodt Completes Full Enrollment Of Its Phase 3 Clinical Trial For StrataGraft® Regenerative Skin Tissue

-- Pivotal Phase 3 study is evaluating efficacy and safety of investigational regenerative skin tissue in adults with deep partial-thickness burns --

Mallinckrodt And Washington University St. Louis Select First Collaborative Research Endeavor

Mallinckrodt And Washington University St. Louis Select First Collaborative Research Endeavor

-- Discovery program aimed at identifying potential new drugs targeting chronic itch, a serious condition spanning multiple disorders --

Data Published On Acthar® Gel (repository Corticotropin Injection) Disease Status And Utilization Patterns In Uveitis Patients In Journal Of Ocular Pharmacology And Therapeutics

Data Published On Acthar® Gel (repository Corticotropin Injection) Disease Status And Utilization Patterns In Uveitis Patients In Journal Of Ocular Pharmacology And Therapeutics

-- Physicians report improved overall disease status in 84 percent of patients after Acthar Gel therapy --

Mallinckrodt Achieves Top Score In 2019 Corporate Equality Index For Third Year In A Row, Recognized As A Best Place To Work For LGBTQ Equality

Mallinckrodt Achieves Top Score In 2019 Corporate Equality Index For Third Year In A Row, Recognized As A Best Place To Work For LGBTQ Equality

-- Company earns 100 percent on Human Rights Campaign Foundation's 17th annual scorecard on LGBTQ Workplace Equality --

More Mud on Johnson & Johnson?

More Mud on Johnson & Johnson?

There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.

TheStreet Quant Rating: D (Sell)